Details checkedStatus confirmedHistorical/discontinuedCheckedcompany

FX-322 by Frequency Therapeutics

Also known as: FX-322, FX-322-208

Frequency Therapeutics

Primary source

Company

Frequency Therapeutics

Program Type

Therapeutic

Modality

Regenerative Medicine

Stage

Phase 2

Status

Discontinued

Target Gene

—

Route / Mode

Intratympanic injection

Confidence

96%

Status Confidence

Status confirmed

Evidence Strength

Needs more support

Last Reviewed

2026-05-31

Geography

United States

Population

adult

Trial IDs

Mechanism

Intratympanic small-molecule combination was designed to activate cochlear progenitor cells and regenerate sensory cells needed for hearing.

Indications

Hearing Loss Sensorineural Hearing Loss Noise-Induced Hearing Loss Sudden Sensorineural Hearing Loss

Notes

Field-shaping hearing-regeneration program that drove broad investor and scientific attention before a negative Phase 2b readout ended the franchise. Generated dose-arm rows from FX-322 trials are treated as covered by this canonical program record, not as separate programs.

Evidence & Sources

3 structured sources

company

Supports: canonicalName, aliases, stage, status, indications, route, notes

IDs: FX-322, FX-322-208

Open

company

Supports: mechanism, route, notes

IDs: FX-322

Open

clinicaltrials

Supports: trialIds, stage, route, indications